Ewing R, Tate G M, Hetherington J W
Br J Urol. 1987 Jan;59(1):53-8. doi: 10.1111/j.1464-410x.1987.tb04579.x.
Urinary fibrin/fibrinogen degradation products (FDPs) were measured in 210 specimens from 174 patients with newly or previously diagnosed transitional cell carcinoma of the bladder. They were detected in 94% of patients with deeply invasive bladder tumours (pT2-4) compared with 17% of superficial tumours. Microalbuminuria (greater than 50 micrograms/g creatinine) was also found in 80% of patients with pT2-4 lesions. Both were compared with urine cytology. Urinary FDPs are markers of bladder tumour invasion. Our results suggest that urinary FDPs are not of value in screening for the presence of bladder neoplasia but their role may be in following patients with superficial bladder tumours to detect those tumours which become invasive. The mode of excretion of the FDPs in the urine is discussed.
对174例新诊断或既往诊断为膀胱移行细胞癌患者的210份样本进行了尿纤维蛋白/纤维蛋白原降解产物(FDPs)检测。在94%的浸润性膀胱肿瘤(pT2 - 4)患者中检测到FDPs,而浅表性肿瘤患者中这一比例为17%。在80%的pT2 - 4期病变患者中还发现了微量白蛋白尿(大于50微克/克肌酐)。将这两项指标与尿细胞学检查结果进行了比较。尿FDPs是膀胱肿瘤浸润的标志物。我们的结果表明,尿FDPs在筛查膀胱肿瘤方面没有价值,但其作用可能在于对浅表性膀胱肿瘤患者进行随访,以检测那些发生浸润的肿瘤。文中讨论了FDPs在尿液中的排泄方式。